Skip to main content

Table 3 Different categories of drugs used in preclinical and clinical studies in ATC

From: Therapeutic advances in anaplastic thyroid cancer: a current perspective

Chemotherapeutic agents
 Topoisomerase inhibitor Doxorubicin, Etoposide
 Microtubule assembly Paclitaxel, Vinorelbine, Docetaxel
 DNA crosslinking agents Cisplatin, Carboplatin, Cyclophosphamide, Neoplatin
 Nucleoside Analog Gemcitabine, 5- fluorouracil
Targeted inhibitors/antibodies
 ALK1 GSK461364A
 Akt MK-2206 2HCL, Perifosine, GSK690693, GDC-0068, AT7867
 Aurora Kinases MK-0457 (VX-680), SNS-314 mesylate, ZM447439, AZD1152 and MLN8054
 Bcl2 Obatoclax
 CDK BP14
 EGFR Cetuximab (C225), Manumycin A, Geldanamycin, Gefitinib (ZD1839)
 HSP90 Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin, NVP-A0Y922, SNX5422
 I-κB Ciglitazone (upregulates TrailR1, −R2)
 PARP Olaparib
 PD-1 receptor Pembrolizumab, PDR001
 PDL-1 Durvalumab, Atezolizumab, FAZ053
 CTLA4 Tramelimumab
 TGF-β LY2157299, SB 525334, LY2109761, Perfenidone, GW788388
 SMO (Wnt signaling pathway) LDE225, LY2940680, PF-5274857, SANT-1
 γ-secretase RO4929097, LY-411575
Anti-angiogenic agents
 Vascular disrupting agent Combretastatin A4 phosphate (CA4P), Fosbretabulin
 VEGF Bevacizumab, AZD2171, Cediranib
Multi-Kinase inhibitors
 VEGF 1, 2 and 3, PDGFR and c-KIT Axitinib (AG-013736), Pazopanib
 VEGFR1, 2 and 3, EGFR and RET kinases Vandetanib
 VEGFR-1, PDGFR, RET, FLT-3 and CSF-1R Sunitinib
 VEGFR2, EGFR and RET CLM94
 BCR-ABL, PDGFR and c-kit Imatinib
 VEGFR 1, 2, PDGFRβ, RET, BRAF and c-Kit Sorafenib (Bay43–9006, Nexavar)
 VEGFR-1, −2 and − 3, PDGFRβ, RET, FGFR −1, − 2, −3, −4 and c-KIT Lenvatinib (E7080)
 VEGFR 2, RET, MET, kit Cabozantinib
 VEGFR −1, − 2, −3, RET, kit, PDGFR Motesanib
 VEGFR − 1, −3, PDGFR, FGFR1–3 Ninetedanib
 RET, PDGFR, FGFR, FLT3, kit Ponatinib
 MET, ALK, ROS1 Crizotinib
Epigenetic modifiers
 HDAC inhibitors Valproic acid, Thailandepsin A (TDP-A), Trichostatin A (TSA), Suberoyl Amide Hydroxamic Acid (SAHA), N-hydroxy-7-(2-naphthylthio)heptanomide (HNHA)
 BET inhibitors JQ1, I-BET762
Miscellaneous
 HDACs, EGFR (dual inhibitor) CUDC-101
 Proteosome inhibitors Carfilzomib, Bortezomib (PS-341)
 PPARγ agonists Rosiglitazone, RS5444, Pioglitazone, Troglitazone